Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Journal of Neuroscience
  • Log in
  • My Cart
Journal of Neuroscience

Advanced Search

Submit a Manuscript
  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Collections
    • Podcast
  • ALERTS
  • FOR AUTHORS
    • Information for Authors
    • Fees
    • Journal Clubs
    • eLetters
    • Submit
  • EDITORIAL BOARD
  • ABOUT
    • Overview
    • Advertise
    • For the Media
    • Rights and Permissions
    • Privacy Policy
    • Feedback
  • SUBSCRIBE
PreviousNext
Featured ArticleResearch Articles, Neurobiology of Disease

Disruption of Bmal1 Impairs Blood–Brain Barrier Integrity via Pericyte Dysfunction

Ryota Nakazato, Kenji Kawabe, Daisuke Yamada, Shinsuke Ikeno, Michihiro Mieda, Shigeki Shimba, Eiichi Hinoi, Yukio Yoneda and Takeshi Takarada
Journal of Neuroscience 18 October 2017, 37 (42) 10052-10062; DOI: https://doi.org/10.1523/JNEUROSCI.3639-16.2017
Ryota Nakazato
1Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kanazawa, Ishikawa 920-1192, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenji Kawabe
2Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daisuke Yamada
2Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinsuke Ikeno
1Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kanazawa, Ishikawa 920-1192, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michihiro Mieda
3Department of Molecular Neuroscience and Integrative Physiology, Faculty of Medicine, Kanazawa University, Kanazawa, Ishikawa 920-8640, Japan, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michihiro Mieda
Shigeki Shimba
4Department of Health Science, College of Pharmacy, Nihon University, Chiba 274-8555, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eiichi Hinoi
1Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kanazawa, Ishikawa 920-1192, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukio Yoneda
1Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kanazawa, Ishikawa 920-1192, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takeshi Takarada
1Laboratory of Molecular Pharmacology, Division of Pharmaceutical Sciences, Kanazawa University Graduate School, Kanazawa, Ishikawa 920-1192, Japan,
2Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Circadian rhythm disturbances are well established in neurological diseases. However, how these disruptions cause homeostatic imbalances remains poorly understood. Brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein 1 (Bmal1) is a major circadian clock transcriptional activator, and Bmal1 deficiency in male Bmal1nestin−/− mice induced marked astroglial activation without affecting the number of astrocytes in the brain and spinal cord. Bmal1 deletion caused blood–brain barrier (BBB) hyperpermeability with an age-dependent loss of pericyte coverage of blood vessels in the brain. Using Nestin-green fluorescent protein (GFP) transgenic mice, we determined that pericytes are Nestin-GFP+ in the adult brain. Bmal1 deletion caused Nestin-GFP+ pericyte dysfunction, including the downregulation of platelet-derived growth factor receptor β (PDGFRβ), a protein necessary for maintaining BBB integrity. Knockdown of Bmal1 downregulated PDGFRβ transcription in the brain pericyte cell line. Thus, the circadian clock component Bmal1 maintains BBB integrity via regulating pericytes.

SIGNIFICANCE STATEMENT Circadian rhythm disturbances may play a role in neurodegenerative disorders, such as Alzheimer's disease. Our results revealed that one of the circadian clock components maintains the integrity of the blood–brain barrier (BBB) by regulating vascular-embedded pericytes. These cells were recently identified as a vital component for the control of BBB permeability and cerebral blood flow. Our present study demonstrates the involvement of circadian clock component Bmal1 in BBB homeostasis and highlights the role of Bmal1 dysfunction in multiple neurological diseases.

  • blood–brain barrier
  • Clock gene
  • pericyte

Introduction

Circadian rhythms are observed in a variety of physiological processes, including sleep/wake cycles, in organisms ranging from bacteria to mammals. Circadian rhythmicity is believed to be generated at the cellular level by circadian core oscillators, which not only reside in the suprachiasmatic nucleus (SCN) of the hypothalamus but also in non-SCN brain regions and peripheral tissues (Young et al., 2001; Storch et al., 2002; Mühlbauer et al., 2004; Shimba et al., 2005). Circadian rhythms are generated by circadian locomotor output cycles protein kaput (clock) gene feedback loops. The positive loop is comprised of brain and muscle aryl hydrocarbon receptor nuclear translocator-like protein-1 (Bmal1) and Clock. The Bmal1/Clock complex binds to the E-box motif and regulates the transcription of various genes. The positive loop also promotes the transcription of genes in the negative loop, including period (Per) and cryptochrome (Cry). These proteins negatively regulate gene transcription by inhibiting the transcriptional activity of the Bmal1/Clock complex. Once the Per/Cry repressor complex is ubiquitinated and degraded by the proteasome, the Bmal1/Clock complex activates a new transcriptional cycle with oscillatory rhythmicity (Gekakis et al., 1998; Griffin et al., 1999; Kume et al., 1999; Yamaguchi et al., 2000).

Abnormal sleep behaviors are commonly observed in patients with psychiatric and neurodegenerative diseases. Several studies have suggested that the disruption of circadian rhythm machinery is involved in the pathogenesis of these diseases (Schibler, 2007; Wulff et al., 2010; Kondratova and Kondratov, 2012). Musiek et al. (2013) reported that mice with a targeted deletion of Bmal1 in the brain showed impaired neuronal connectivity and severe age-dependent astrogliosis, indicating that impaired clock gene function may lead to neurodegeneration. However, how disruption of circadian clock system causes this homeostatic imbalance in the brain remains poorly understood.

Here, we show that gene ablation of Bmal1, a central regulator of the positive feedback loop of the circadian clock system, disrupts blood–brain barrier (BBB) integrity. Bmal1 deficiency leads to pericyte dysfunction, BBB hyperpermeability, and marked astrogliosis. Thus, our data demonstrate that Bmal1 function regulates BBB homeostasis in the brain and provide insight into the development of new therapeutic/diagnostic strategies for patients with psychiatric and neurodegenerative diseases.

Materials and Methods

Animals.

Bmal1−/− mice (Shimba et al., 2011), Bmal1fl/fl mice (stock #007688, The Jackson Laboratory; Storch et al., 2007), Nestin-Cre mice (stock #003771, The Jackson Laboratory; Tronche et al., 1999), Synapsin I-Cre (Zhu et al., 2001), S100β-Cre (Tanaka et al., 2008), and Nestin-GFP mice (Mignone et al., 2004) were backcrossed with C57BL/J mice at least six times. Mice were bred under the following standard animal housing conditions: 23 ± 1°C, 55% humidity, 12 h light/dark cycle, and standard laboratory food and water available ad libitum. RNA was extracted from the calvaria at different diurnal times. Zeitgeber time (ZT) 0 and ZT12 are defined as the time of lights-on and lights-off, respectively. Genotyping was performed by PCR using tail genomic DNA with the primers listed in Table 1. The study protocol was approved by the Committee for Ethical Use of Experimental Animals at Kanazawa University in Kanazawa, Japan.

View this table:
  • View inline
  • View popup
Table 1.

List of primers used for genotyping in this study

Open field test.

Adult male mice were tested using a 42.2 cm2 wood board enclosure with 30 cm walls. Mice were placed at the center of open field, and images were recorded for 10 min. Quantitative analyses were performed using ImageJ software (National Institutes of Health). The x-y coordinates of the mice in each picture were determined using ImageJ to represent the center of mass of the animal. The total distance traveled represents the sum of all displacements of the mouse.

Immunohistochemistry.

Adult male mice at age 8–12 weeks were deeply anesthetized with diethyl ether before an intracardial perfusion with saline and 4% paraformaldehyde. Brains and spinal cords were removed, postfixed overnight, and cryoprotected in 30% sucrose. For double-immunohistochemical staining, frozen coronal sections were cut at a thickness of 30 μm using a cryostat (CM 3050, Leica). Sections were incubated in a blocking solution for 1 h followed by incubation with the primary antibodies for 24 h at 4°C. After washing in PBS, sections were incubated for 2 h at room temperature with the secondary antibodies. The antibodies used in this study are listed in Table 2. Confocal images were acquired using LSM710 and Zen 2009 software (Carl Zeiss). Quantitative image analyses were performed using ImageJ software. Pericyte coverage (Desmin/CD31 or CD13/CD31) was quantified using ImageJ to measure the percentage area of Desmin+ or CD13+ pericytes versus CD31+ vessels. The CD31+ area per square millimeter was defined as the vascular density.

View this table:
  • View inline
  • View popup
Table 2.

List of antibodies used in this study

BBB permeability assay.

Adult male mice at age 8–12 weeks were intravenously injected with 100 mg/kg Evans Blue [molecular weight (MW), 961 Da; Tocris Bioscience] or 100 mg/kg EZ-link sulfo NHS-biotin (MW, 443 Da; Thermo Fisher Scientific). Mice were perfused with saline (Evans Blue) or 4% paraformaldehyde (EZ-link sulfo NHS-biotin) within 24 h after the tracer injection. Sections obtained from biotin-injected mice were stained with Alexa Fluor 488–streptavidin (1:400; Invitrogen) and anti-laminin/Alexa Fluor 546-conjugated goat anti-rabbit IgG. Frozen brain coronal sections were viewed with a LSM710 confocal microscope. The leakage of injected biotin into brain parenchyma was quantified using ImageJ software.

Transfection with siRNA.

The rodent brain pericyte cell line TR-PCT1 was a gift from Dr. Emi Nakashima (Keio University, Tokyo, Japan; Asashima et al., 2002). TR-PCT1 cells were transfected with 10 nm Bmal1 siRNA (Sigma Chemical) using Lipofectamine/RNAiMAX (Invitrogen). mRNA expression was determined using quantitative PCR (qPCR) 48 h after transfection.

Determination of mRNA expression.

Cells were washed twice with PBS. The extraction of total RNA using ISOGEN was completed according to the manufacturer instructions. Quantification of PCR products was performed with an iQ SYBR Green Super Mix (BIO-RAD) using real time-based RT-PCR and a Mx3000P qPCR System (Agilent Technologies). The relative amount of each transcript was normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh) expression from a real time-based RT-PCR(Takarada et al., 2012a). The primer sequences used for qPCR included Pdgfrb: 5′-TATGCTGCAGAACTCGATGG-3′, 5′-CCACTTTGAAAGGCAAGGAG-3′; and Gapdh: 5′-CAACTCCCTCAAGATTGTCAGCAA-3′, 5′-GGCATGGACTGTGGTCATGA-3′.

Statistical analysis.

All data are presented as the mean ± SEM. Group means were compared using two-way ANOVA with the Bonferroni post hoc test. p values of <0.05 were considered to be statistically significant. Each result is representative of three or more independent experiments.

Results

Bmal1 deletion in Bmal1nestin−/− mice causes astroglial activation in the brain

A previous study by Musiek et al. (2013) demonstrated that brain-specific Bmal1-knock-out mice, generated by crossing Bmal1fl/fl mice with Nestin-Cre mice, exhibited marked age-dependent cerebral astrogliosis, synaptic degeneration, and behavioral abnormalities, including novelty-induced hyperactivity. We confirmed these phenotypes in Nestin-Cre;Bmal1fl/fl (Bmal1nestin−/−) mice and evaluated whether the astrogliosis observed in Bmal1nestin−/− was due an increase in the total number of astrocytes or an increase in the activation of existing astrocytes. As previously described (Musiek et al., 2013), Bmal1nestin−/− mice exhibited novelty-induced hyperactivity during open-field testing (Control, n = 9; Bmal1nestin−/−, n = 4; p = 0.0006; Fig. 1A). GFAP+ cells were significantly elevated in the cerebral cortex and hippocampal dentate gyrus of Bmal1nestin−/− mice (p = 0.002); however, the number of S100β+ cells, another astrocyte marker, as well as the number of other neuronal cell markers, including NeuN, CD11b, and Iba1, was comparable in the cerebral cortex between control and Bmal1nestin−/− mice (n = 3/group; Fig. 1B–D). The percentage of GFAP+/S100β+ cells was significantly elevated in Bmal1nestin−/− mice (p < 0.001; Fig. 1D). Similar results were observed in the spinal cord of Bmal1nestin−/− mice (n = 3/group; number of cells, p = 0.003; percentage of GFAP+/S100β+ cells, p = 0.008; Fig. 1E). These data suggest that the deletion of Bmal1 does not increase the number of astrocytes but rather increases the activation of pre-existing astrocytes.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Astroglial activation in Bmal1nestin−/− mice. A, Open field test to measure novelty-induced locomotor activity of Bmal1nestin−/− mice at age 8–12 weeks (control, n = 9; Bmal1nestin−/−, n = 4). B, Immunohistochemical analysis of GFAP in the cerebral cortex and hippocampal dentate gyrus of Bmal1nestin−/− mice at age 8–12 weeks. The area surrounded by a white dashed line denotes the granule cell layer of dentate gyrus. C, Immunohistochemical analysis of NeuN, S100β, and Iba1 in the cerebral cortex of Bmal1nestin−/− mice at age 8–12 weeks. D, Quantification of NeuN+, GFAP+, S100β+, and Iba1+ cells in the cerebral cortex of control and Bmal1nestin−/− mice at age 8–12 weeks (control, n = 3; Bmal1nestin−/−, n = 3). E, Immunohistochemical analysis of GFAP (red) and S100β (green) in the spinal cord of Bmal1nestin−/− mice (control, n = 3; Bmal1nestin−/−, n = 3). The area surrounded by a white dashed line denotes the dorsal horn of the spinal cord. The number of positive cells per square millimeter was calculated. **p < 0.01 when compared with littermate controls.

Bmal1 deletion in Bmal1nestin−/− mice causes BBB hyperpermeability via pericyte loss

Astrocytes contribute to the regulation of neural transmission and progression of neurodegeneration and, along with endothelial cells and pericytes in the CNS, are a key component of BBB (Zloković, 2008; Segura et al., 2009). A decline in BBB integrity induces the leakage of blood-derived factors and subsequent astroglial activation (Adornato and Lampert, 1971; Brett et al., 1995; Schachtrup et al., 2010). To determine the cause of astrocyte activation in Bmal1nestin−/− mice, we assessed BBB integrity in these mice at age 8–10 weeks. We evaluated the water content of Bmal1nestin−/− brains by measuring the ratio of wet weight to dry weight. The water content of the brain was significantly higher in Bmal1nestin−/− mice when compared with control mice (control, n = 6; Bmal1nestin−/−, n = 5; p = 0.027; Fig. 2A). Bmal1nestin−/− mice showed an increased vascular permeability to Evans Blue dye (100 mg/kg; Fig. 2B) and biotin (100 mg/kg; n = 3/group; percentage of control leakage area, p = 0.014; Fig. 2C) throughout the CNS parenchyma, suggesting that Bmal1 deletion leads to BBB hyperpermeability.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

BBB hyperpermeability in Bmal1nestin−/− mice. A, Wet/dry weight ratios of control and Bmal1nestin−/− mice (control, n = 6; Bmal1nestin−/−, n = 5). B, Confocal images of the cerebral cortex of mice injected with Evans Blue after 24 h of circulation. C, Confocal images of the cerebral cortex in mice injected with biotin after 24 h of circulation. Sections were stained with Alexa Fluor 488–streptavidin (1:400; Invitrogen) and anti-laminin/Alexa Fluor 546-conjugated goat anti-rabbit IgG. The leakage area of biotin was quantified (control, n = 3; Bmal1nestin−/−, n = 3). D, Three-dimensional reconstruction of confocal image z-stacks of cerebral cortex vasculatures depicted by CD31 (endothelial cells), Desmin (pericytes), CD13 (pericytes), and PDGFRβ (pericytes) in Bmal1nestin−/− mice at age 8–12 weeks. Vascular density, pericyte coverage, and the number of PDGFRβ+ cells were calculated (control, n = 3; Bmal1nestin−/−, n = 3). E, Confocal images of Aqp4 (astrocyte end-feet) and CD31 in the cerebral cortex of Bmal1nestin−/− mice. The Aqp4+ area was calculated (control, n = 3; Bmal1nestin−/−, n = 3). *p < 0.05; **p < 0.01 when compared with littermate controls.

Next, we assessed endothelial cells and pericytes, which are essential for the maintenance of BBB integrity. Pericytes are embedded in the basement membrane of blood vessels, and the pericyte coverage of blood vessels in the CNS inversely correlates with BBB permeability in embryos and adult brains (Bell et al., 2010; Daneman et al., 2010). Double-immunohistochemical analysis for CD31 (marker for endothelial cells) and pericyte markers, including Desmin and CD13, clearly showed the progressive loss of pericyte coverage in the cerebral cortex of 10-week-old Bmal1nestin−/− mice compared with littermate controls (n = 3/group; Desmin, p = 0.044; CD13, p = 0.001; Fig. 2D). Platelet-derived growth factor receptor β (PDGFRβ) is another pericyte marker. Bmal1nestin−/− mice showed a drastic decrease in the number of PDGFRβ+ cells in the cerebral cortex (n = 3/group; p = 0.004; Fig. 2D). Aquaporin 4 (Aqp4) is a water channel protein that is expressed in astrocyte end-feet nearest the neurovascular unit, and it is involved in brain volume homeostasis and in the pathogenesis of brain edema (Nielsen et al., 1997). In control mice, Aqp4 expression was observed in the CD31+ endothelial lining of the vasculature, namely in perivascular glial processes, as reported previously (Nielsen et al., 1997). However, Bmal1nestin−/− mice exhibited a drastic decrease in the Aqp4+ area in the cerebral cortex (n = 3/group; p = 0.021; Fig. 2E).

Moreover, astroglial activation and the loss of pericyte marker expression were age dependent. These parameters were not observed in Bmal1nestin−/− mice at age 1 and 2 weeks, but they were detected at age 4 weeks (n = 3/group; number of GFAP+ cells, p = 0.019; percentage of Desmin+ cells, p = 0.045; percentage of CD13+ cells, p = 0.034; number of PDGFRβ+ cells, p = 0.048; Fig. 3A,B). Thus, our results indicate that Bmal1 deletion causes pericyte dysfunction and BBB hyperpermeability.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Cerebral astroglial activation and the loss of pericyte marker expression in Bmal1nestin−/− mice are age dependent. A, Confocal images of GFAP, Desmin, CD13, and PDGFRβ in the cerebral cortex of Bmal1nestin−/− mice at 1, 2, and 4 weeks of age. B, Quantification of GFAP+ and PDGFRβ+ cells in the cerebral cortex of control and Bmal1nestin−/− mice at various time points. The percentage areas of Desmin+ or CD13+ pericytes vs CD31+ vessels were calculated (control, n = 3; Bmal1nestin−/−, n = 3). *p < 0.05 compared with littermate controls.

Bmal1 deletion causes dysfunction of Nestin-GFP+ pericytes in the brain

The loss of pericytes and BBB hyperpermeability occurs in Nestin-Cre-targeted and/or lineage cells that are Bmal1 deficient. Although the typical lineage cells of Nestin-Cre-targeted cells are neurons and astrocytes, neuron-specific (Bmal1synapsinI−/−) and astrocyte-specific (Bmal1s100β−/−) Bmal1 knock-out mice did not exhibit any abnormal phenotypes, including hyperactivity in open-field testing (Fig. 4A), astroglial activation (Fig. 4B), and decreased pericyte coverage and PDGFRβ expression (Fig. 4C) in the brain. The intermediate filament protein Nestin, which was first reported as a marker of neuroectoderm progenitors (Lendahl et al., 1990), is expressed in pericytes (Alliot et al., 1999; Dore-Duffy et al., 2006). In transgenic mice expressing GFP under control of the 5.8 kb promoter and 1.8 kb second intron of the Nestin gene (Nestin-GFP+; Mignone et al., 2004; Ono et al., 2014), Nestin-GFP+ cells were observed throughout the cerebral cortex (Fig. 5A), hippocampus (Fig. 5-1A), and the spinal cord (Fig. 5B). Immunohistochemical analysis clearly revealed that Nestin-GFP+ cells were positive for Bmal1 in the cerebral cortex (Fig. 5C). Next, we assessed the cell types of Nestin-GFP+ cells via immunohistochemical analysis. Nestin-GFP+ cells in the cerebral cortex were negative for NeuN, GFAP, and CD11b and were positive for Desmin, CD13, and PDGFRβ (Fig. 5D,E, and Fig. 5-1B,C). In addition, these cells were present near CD31+ endothelial cells and α-smooth muscle actin (αSMA)+ vascular smooth muscle cells, indicating that brain pericytes are Nestin-GFP+ cells.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Neuron-specific (Bmal1synapsinI−/−) and astrocyte-specific (Bmal1s100β−/−) Bmal1 knock-out mice do not exhibit the same abnormal phenotypes as Bmal1nestin−/− mice. A, Open-field test to measure novelty-induced locomotor activity in Bmal1synapsinI−/− (control, n = 3; Bmal1synapsinI−/−, n = 3) and Bmal1100β−/− mice (control, n = 10; Bmal1s100β−/−, n = 6) at 8–12 weeks of age. B, Immunohistochemical analysis of GFAP in the cerebral cortex of Bmal1synapsinI−/− and Bmal1s100β−/− mice at age 8–12 weeks. The number of positive cells per square millimeter was calculated. C, Confocal image of cerebral cortex vasculatures depicted by CD31, Desmin, CD13, and PDGFRβ staining in Bmal1synapsinI−/− and Bmal1s100β−/− mice at age 8–12 weeks. The percentage area of Desmin+ or CD13+pericytes vs CD31+ vessels and the number of PDGFRβ+ cells were calculated.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Pericytes in the brain are Nestin-GFP+. A, B, Confocal image of GFP (green) and Hoechst 33342 DNA staining (blue) in the cerebral cortex (A) or spinal cord (B) of Nestin-GFP transgenic mice at age 8–12 weeks. The area surrounded by a white dashed line denotes the dorsal horn of the spinal cord. C, Immunohistochemical analysis of Bmal1 in the cerebral cortex of Nestin-GFP+ mice at 8–12 weeks of age. D, Immunohistochemical analysis of NeuN, GFAP, CD11b, CD31, αSMA, Desmin, CD13, and PDGFRβ in the cerebral cortex of Nestin-GFP+ mice at age 8–12 weeks. The area surrounded by a white dashed line denotes the αSMA+ area. Arrows indicate the PDGFRβ+ cells. E, The percentage of each marker-positive cell type among Nestin-GFP+ cells in a confocal image from the immunohistochemical analysis presented in D (n = 3; 2–3 slices per independent mouse). Figure 5-1. Additional data for Nestin-GFP+ cells in the brain. A, Confocal image of GFP (green) and Hoechst 33342 DNA staining (blue) in the hippocampal dentate gyrus and CA1 and CA3 regions of Nestin-GFP transgenic mice at 8–12 weeks of age. B, Low-magnification images of immunohistochemical staining for CD31, Desmin, CD13, and PDGFRβ in the cerebral cortex of Nestin-GFP+ mice. C, Representative confocal laser-scanning orthoimage of z-stacks of CD31, Desmin, and CD13 in the cerebral cortex of Nestin-GFP+ mice.

Figure 5-1

Additional data for Nestin-GFP+ cells in the brain. A, Confocal image of GFP (green) and Hoechst 33342 DNA staining (blue) in the hippocampal dentate gyrus and CA1 and CA3 regions of Nestin-GFP transgenic mice at 8-12 weeks of age. B, Low-magnification images of immunohistochemical staining for CD31, Desmin, CD13 and PDGFRβ in the cerebral cortex of Nestin-GFP+ mice. C, Representative confocal laser-scanning orthoimage of z-stacks of CD31, Desmin and CD13 in the cerebral cortex of Nestin-GFP+ mice. Download Figure 5-1, TIF file

To determine whether the Bmal1 deletion changes the properties of Nestin-GFP+ pericytes, we generated the global Bmal1-knock-out (Bmal1−/−) mice expressing the GFP under the Nestin promoter (Nestin-GFP+Bmal1−/−) by crossing Bmal1−/− mice with Nestin-GFP mice (n = 4/group). In 8-week-old Nestin-GFP+Bmal1−/− mice, GFAP+-activated astrocytes were markedly increased surrounding the Nestin-GFP+ cells in the cerebral cortex (Fig. 6A). On the other hand, the number of Nestin-GFP+ cells were comparable between Nestin-GFP+Bmal1+/+ and Nestin-GFP+Bmal1−/− mice (Fig. 6A,G). In addition, the areas of CD31+ endothelial cells (vascular density; Fig. 6B,G) and αSMA+ smooth muscle cells (Fig. 6C,G) were comparable between Nestin-GFP+Bmal1+/+ and Nestin-GFP+Bmal1−/− mice. However, the significant decreases were seen in the percentages of Desmin+ (p = 0.008; Fig. 6D,G), CD13+ (p = 0.002; Fig. 6E,G), and PDGFRβ+ cells (p < 0.001; Fig. 6F,G) among Nestin-GFP+ cells. These results suggesting that Bmal1 deletion should not cause the “loss” of pericyte, but the “dysfunction” of Nestin-GFP+ pericytes in CNS.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Deficiency of Bmal1 downregulates PDGFRβ expression in Nestin-GFP+ pericytes. A–F, Immunohistochemical analysis of GFAP (A), CD31 (B), αSMA (C), Desmin (D), CD13 (E), and PDGFRβ (F) in the cerebral cortex of Nestin-GFP+Bmal1−/− and Nestin-GFP+Bmal1+/+ mice. The presented images are three-dimensional reconstructions of z-stacks. G, The number of positive cells among Nestin-GFP+ cells per square millimeter, vascular density, and the αSMA+ area were calculated (Nestin-GFP+Bmal1+/+, n = 4; Nestin-GFP+Bmal1−/−, n = 4). **p < 0.01 compared with littermate controls. H, Determination of mRNA expression levels for Pdgfrb in the brain pericyte TR-PCT1 cells transfected with Bmal1 siRNA (siControl, n = 5; siBmal1, n = 3). **p < 0.01 compared with cells transfected with siControl.

PDGFRβ is a receptor for PDGF-BB secreted from endothelial cells. Precise PDGF-BB/PDGFRβ signaling is essential for maintaining BBB integrity in the CNS (Winkler et al., 2011). Mice with partially disrupted PDGF-BB/PDGFRβ signaling exhibited age-dependent BBB breakdown (Armulik et al., 2010; Daneman et al., 2010). Therefore, we assessed whether circadian clock proteins regulate PDGFRβ expression in pericytes. Pdgfrb expression was evaluated in the TR-PCT1 brain pericyte cell line. Bmal1 knockdown by siRNA decreased the expression of Pdgfrb in the TR-PCT1 cells (siControl, n = 5; siBmal1, n = 3; p < 0.001; Fig. 6H). These experiments revealed that PDGFRβ transcription is positively controlled by Bmal1, suggesting that the decreased Bmal1 expression in Nestin-GFP+ pericytes is responsible for downregulating PDGFRβ expression in Bmal1nestin−/− mice.

Discussion

The essential finding of this study is that the disruption of Bmal1, which is part of the positive feedback loop of the circadian clock system, induces pericyte dysfunction and BBB hyperpermeability. In contrast to the vessels in peripheral organs, BBB restricts the entry of polar molecules into the brain (Mann et al., 1985; Zloković et al., 1985a,b; Zlokovic and Apuzzo, 1997). However, some molecules can be transported into the brain via specific transporters expressed in the brain endothelium under physiological or pathological conditions (Zloković et al., 1987, 1990). In addition, several BBB peptide transport mechanisms exist, including receptor-mediated, adsorptive-mediated, carrier-mediated, and nonspecific passive diffusion (Zloković, 1995). Clinical studies have also reported BBB dysfunction and brain inflammation in patients with psychiatric disorders (Shalev et al., 2009; Najjar et al., 2013). The previous report by Musiek et al. (2013) showed that Bmal1nestin−/− mice exhibited several neuronal deficits, such as axonal terminal degeneration, disrupted resting-state functional connectivity, and widespread astrocyte activation. Our current findings support the hypothesis that decreased expression of the circadian clock component induces psychiatric or neurodegenerative disease by decreasing BBB integrity. Although many studies have identified the functional importance of clock genes in the brain, we are the first to directly demonstrate the involvement of the circadian clock component in BBB integrity.

Pericytes are embedded within the vascular basement membrane of blood vessels and control BBB permeability and cerebral blood flow (Winkler et al., 2011). Accumulating evidence suggests that pericyte degeneration induces BBB breakdown and neuronal degeneration following the accumulation of blood-derived neurotoxins (Mann et al., 1985; Zloković et al., 1990; Bell et al., 2010) in complex neurological disorders, such as Alzheimer's disease (Zloković et al., 1985a,b, 1987), amyotrophic lateral sclerosis (Zloković, 1995), and retinopathy related to type 2 diabetes mellitus (Nielsen et al., 1997; Zlokovic and Apuzzo, 1997). Bmal1nestin−/− mice exhibited pericyte dysfunction, BBB hyperpermeability, and marked astrocyte activation. These data strongly indicate that genetic disruption of the circadian clock protein affects BBB homeostasis via pericyte dysfunction in vivo.

Our observation that Bmal1nestin−/− mice exhibit pericyte dysfunction, BBB hyperpermeability, and astrocyte activation provides a novel mechanism as to how circadian clock component Bmal1 regulates pericyte function. PDGF-BB is secreted from endothelial cells and binds to the PDGFRβ on pericytes, which is essential for the recruitment, proliferation, migration, and attachment of pericytes (Winkler et al., 2011). Studies in mouse models with partially disrupted PDGF-BB/PDGFRβ signaling showed an age-dependent BBB breakdown (Armulik et al., 2010; Daneman et al., 2010). Our experiments in Nestin-GFP+Bmal1−/− mice demonstrated that the deletion of Bmal1 does not affect the number of Nestin-GFP+ pericytes but rather changes the properties of pre-existing Nestin-GFP+ pericytes (i.e., decreased PDGFRβ expression). In addition, silencing experiments illustrated that Bmal1 regulates Pdgfrb transcription. Although further experiment should be performed to reveal the mechanisms by which clock genes regulate PDGFRβ expression; therefore, the disruption of the positive loop of the circadian clock may decrease PDGFRβ expression, leading to pericyte dysfunction and reduced BBB integrity.

In conclusion, the circadian clock component Bmal1 regulates BBB homeostasis via regulation of pericyte function. Our findings contribute to an improved understanding of the functions of the non-SCN clock system in a variety of physiological and pathological processes involving BBB hyperpermeability. Thus, Bmal1 may represent a novel target for the discovery and development of therapies for many neurodegenerative and/or psychiatric disorders related to abnormal BBB integrity.

Footnotes

  • This work was supported in part by Grants-in-Aid for Scientific Research on Innovative Areas (26117507 and 16H01332) and for Scientific Research on Innovative Areas (Comprehensive Brain Science Network) to T.T. from the Ministry of Education, Culture, Sports, Science and Technology, Japan; and in part by a research grant to T.T. from the Nakatomi Foundation. We thank Dr. G. Enikolopov (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), Dr. Jamey D. Marth (University of California, Santa Barbara, Santa Barbara, CA), and Dr. Shigeyoshi Itohara (RIKEN Brain Science Institute, Saitama, Japan) for generously providing the Nestin-GFP, Synapsin I-Cre, and S100β-Cre mice, respectively.

  • The authors declare no competing financial interests.

  • Correspondence should be addressed to Takeshi Takarada, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan. takarada{at}okayama-u.ac.jp

References

  1. ↵
    1. Adornato B,
    2. Lampert P
    (1971) Status spongiosus of nervous tissue. Electron microscopic studies. Acta Neuropathol 19:271–289. doi:10.1007/BF00692148 pmid:5004121
    OpenUrlCrossRefPubMed
  2. ↵
    1. Alliot F,
    2. Rutin J,
    3. Leenen PJ,
    4. Pessac B
    (1999) Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin. J Neurosci Res 58:367–378. doi:10.1002/(SICI)1097-4547(19991101)58:3%3C367::AID-JNR2%3E3.0.CO%3B2-T pmid:10518110
    OpenUrlCrossRefPubMed
  3. ↵
    1. Armulik A,
    2. Genové G,
    3. Mäe M,
    4. Nisancioglu MH,
    5. Wallgard E,
    6. Niaudet C,
    7. He L,
    8. Norlin J,
    9. Lindblom P,
    10. Strittmatter K,
    11. Johansson BR,
    12. Betsholtz C
    (2010) Pericytes regulate the blood-brain barrier. Nature 468:557–561. doi:10.1038/nature09522 pmid:20944627
    OpenUrlCrossRefPubMed
  4. ↵
    1. Asashima T,
    2. Iizasa H,
    3. Terasaki T,
    4. Hosoya K,
    5. Tetsuka K,
    6. Ueda M,
    7. Obinata M,
    8. Nakashima E
    (2002) Newly developed rat brain pericyte cell line, TR-PCT1, responds to transforming growth factor-beta1 and beta-glycerophosphate. Eur J Cell Biol 81:145–152. doi:10.1078/0171-9335-00227 pmid:11998866
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bell RD,
    2. Winkler EA,
    3. Sagare AP,
    4. Singh I,
    5. LaRue B,
    6. Deane R,
    7. Zlokovic BV
    (2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68:409–427. doi:10.1016/j.neuron.2010.09.043 pmid:21040844
    OpenUrlCrossRefPubMed
  6. ↵
    1. Brett FM,
    2. Mizisin AP,
    3. Powell HC,
    4. Campbell IL
    (1995) Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J Neuropathol Exp Neurol 54:766–775. doi:10.1097/00005072-199511000-00003 pmid:7595649
    OpenUrlCrossRefPubMed
  7. ↵
    1. Daneman R,
    2. Zhou L,
    3. Kebede AA,
    4. Barres BA
    (2010) Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 468:562–566. doi:10.1038/nature09513 pmid:20944625
    OpenUrlCrossRefPubMed
  8. ↵
    1. Dore-Duffy P,
    2. Katychev A,
    3. Wang X,
    4. Van Buren E
    (2006) CNS microvascular pericytes exhibit multipotential stem cell activity. J Cereb Blood Flow Metab 26:613–624. doi:10.1038/sj.jcbfm.9600272 pmid:16421511
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gekakis N,
    2. Staknis D,
    3. Nguyen HB,
    4. Davis FC,
    5. Wilsbacher LD,
    6. King DP,
    7. Takahashi JS,
    8. Weitz CJ
    (1998) Role of the CLOCK protein in the mammalian circadian mechanism. Science 280:1564–1569. doi:10.1126/science.280.5369.1564 pmid:9616112
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Griffin EA Jr.,
    2. Staknis D,
    3. Weitz CJ
    (1999) Light-independent role of CRY1 and CRY2 in the mammalian circadian clock. Science 286:768–771. doi:10.1126/science.286.5440.768 pmid:10531061
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kondratova AA,
    2. Kondratov RV
    (2012) The circadian clock and pathology of the ageing brain. Nat Rev Neurosci 13:325–335. doi:10.1038/nrn3208 pmid:22395806
    OpenUrlCrossRefPubMed
  12. ↵
    1. Kume K,
    2. Zylka MJ,
    3. Sriram S,
    4. Shearman LP,
    5. Weaver DR,
    6. Jin X,
    7. Maywood ES,
    8. Hastings MH,
    9. Reppert SM
    (1999) mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop. Cell 98:193–205. doi:10.1016/S0092-8674(00)81014-4 pmid:10428031
    OpenUrlCrossRefPubMed
  13. ↵
    1. Lendahl U,
    2. Zimmerman LB,
    3. McKay RD
    (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60:585–595. doi:10.1016/0092-8674(90)90662-X pmid:1689217
    OpenUrlCrossRefPubMed
  14. ↵
    1. Mann GE,
    2. Zlokovic BV,
    3. Yudilevich DL
    (1985) Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim Biophys Acta 819:241–248. doi:10.1016/0005-2736(85)90179-8 pmid:4041458
    OpenUrlCrossRefPubMed
  15. ↵
    1. Mignone JL,
    2. Kukekov V,
    3. Chiang AS,
    4. Steindler D,
    5. Enikolopov G
    (2004) Neural stem and progenitor cells in nestin-GFP transgenic mice. J Comp Neurol 469:311–324. doi:10.1002/cne.10964 pmid:14730584
    OpenUrlCrossRefPubMed
  16. ↵
    1. Mühlbauer E,
    2. Wolgast S,
    3. Finckh U,
    4. Peschke D,
    5. Peschke E
    (2004) Indication of circadian oscillations in the rat pancreas. FEBS Lett 564:91–96. doi:10.1016/S0014-5793(04)00322-9 pmid:15094047
    OpenUrlCrossRefPubMed
  17. ↵
    1. Musiek ES,
    2. Lim MM,
    3. Yang G,
    4. Bauer AQ,
    5. Qi L,
    6. Lee Y,
    7. Roh JH,
    8. Ortiz-Gonzalez X,
    9. Dearborn JT,
    10. Culver JP,
    11. Herzog ED,
    12. Hogenesch JB,
    13. Wozniak DF,
    14. Dikranian K,
    15. Giasson BI,
    16. Weaver DR,
    17. Holtzman DM,
    18. Fitzgerald GA
    (2013) Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest 123:5389–5400. doi:10.1172/JCI70317 pmid:24270424
    OpenUrlCrossRefPubMed
  18. ↵
    1. Najjar S,
    2. Pearlman DM,
    3. Devinsky O,
    4. Najjar A,
    5. Zagzag D
    (2013) Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence. J Neuroinflammation 10:142. doi:10.1186/1742-2094-10-142 pmid:24289502
    OpenUrlCrossRefPubMed
  19. ↵
    1. Nielsen S,
    2. Nagelhus EA,
    3. Amiry-Moghaddam M,
    4. Bourque C,
    5. Agre P,
    6. Ottersen OP
    (1997) Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 17:171–180. pmid:8987746
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Ono N,
    2. Ono W,
    3. Mizoguchi T,
    4. Nagasawa T,
    5. Frenette PS,
    6. Kronenberg HM
    (2014) Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. Dev Cell 29:330–339. doi:10.1016/j.devcel.2014.03.014 pmid:24823376
    OpenUrlCrossRefPubMed
  21. ↵
    1. Schachtrup C,
    2. Ryu JK,
    3. Helmrick MJ,
    4. Vagena E,
    5. Galanakis DK,
    6. Degen JL,
    7. Margolis RU,
    8. Akassoglou K
    (2010) Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-β after vascular damage. J Neurosci 30:5843–5854. doi:10.1523/JNEUROSCI.0137-10.2010 pmid:20427645
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Schibler U
    (2007) The daily timing of gene expression and physiology in mammals. Dialogues Clin Neurosci 9:257–272. pmid:17969863
    OpenUrlPubMed
  23. ↵
    1. Segura I,
    2. De Smet F,
    3. Hohensinner PJ,
    4. Ruiz de Almodovar C,
    5. Carmeliet P
    (2009) The neurovascular link in health and disease: an update. Trends Mol Med 15:439–451. doi:10.1016/j.molmed.2009.08.005 pmid:19801203
    OpenUrlCrossRefPubMed
  24. ↵
    1. Shalev H,
    2. Serlin Y,
    3. Friedman A
    (2009) Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009:278531. doi:10.1155/2009/278531 pmid:19936105
    OpenUrlCrossRefPubMed
  25. ↵
    1. Shimba S,
    2. Ishii N,
    3. Ohta Y,
    4. Ohno T,
    5. Watabe Y,
    6. Hayashi M,
    7. Wada T,
    8. Aoyagi T,
    9. Tezuka M
    (2005) Brain and muscle Arnt-like protein-1 (BMAL1), a component of the molecular clock, regulates adipogenesis. Proc Natl Acad Sci U S A 102:12071–12076. doi:10.1073/pnas.0502383102 pmid:16093318
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Shimba S,
    2. Ogawa T,
    3. Hitosugi S,
    4. Ichihashi Y,
    5. Nakadaira Y,
    6. Kobayashi M,
    7. Tezuka M,
    8. Kosuge Y,
    9. Ishige K,
    10. Ito Y,
    11. Komiyama K,
    12. Okamatsu-Ogura Y,
    13. Kimura K,
    14. Saito M
    (2011) Deficient of a clock gene, brain and muscle Arnt-like protein-1 (BMAL1), induces dyslipidemia and ectopic fat formation. PLoS One 6:e25231. doi:10.1371/journal.pone.0025231 pmid:21966465
    OpenUrlCrossRefPubMed
  27. ↵
    1. Storch KF,
    2. Lipan O,
    3. Leykin I,
    4. Viswanathan N,
    5. Davis FC,
    6. Wong WH,
    7. Weitz CJ
    (2002) Extensive and divergent circadian gene expression in liver and heart. Nature 417:78–83. doi:10.1038/nature744 pmid:11967526
    OpenUrlCrossRefPubMed
  28. ↵
    1. Storch KF,
    2. Paz C,
    3. Signorovitch J,
    4. Raviola E,
    5. Pawlyk B,
    6. Li T,
    7. Weitz CJ
    (2007) Intrinsic circadian clock of the mammalian retina: importance for retinal processing of visual information. Cell 130:730–741. doi:10.1016/j.cell.2007.06.045 pmid:17719549
    OpenUrlCrossRefPubMed
  29. ↵
    1. Takarada T,
    2. Kodama A,
    3. Hotta S,
    4. Mieda M,
    5. Shimba S,
    6. Hinoi E,
    7. Yoneda Y
    (2012a) Clock genes influence gene expression in growth plate and endochondral ossification in mice. J Biol Chem 287:36081–36095. doi:10.1074/jbc.M112.408963 pmid:22936800
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Tanaka M,
    2. Yamaguchi K,
    3. Tatsukawa T,
    4. Nishioka C,
    5. Nishiyama H,
    6. Theis M,
    7. Willecke K,
    8. Itohara S
    (2008) Lack of Connexin43-mediated bergmann glial gap junctional coupling does not affect cerebellar long-term depression, motor coordination, or eyeblink conditioning. Front Behav Neurosci 2:1. doi:10.3389/neuro.08.001.2008 pmid:18958191
    OpenUrlCrossRefPubMed
  31. ↵
    1. Tronche F,
    2. Kellendonk C,
    3. Kretz O,
    4. Gass P,
    5. Anlag K,
    6. Orban PC,
    7. Bock R,
    8. Klein R,
    9. Schütz G
    (1999) Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nat Genet 23:99–103. doi:10.1038/12703 pmid:10471508
    OpenUrlCrossRefPubMed
  32. ↵
    1. Winkler EA,
    2. Bell RD,
    3. Zlokovic BV
    (2011) Central nervous system pericytes in health and disease. Nat Neurosci 14:1398–1405. doi:10.1038/nn.2946 pmid:22030551
    OpenUrlCrossRefPubMed
  33. ↵
    1. Wulff K,
    2. Gatti S,
    3. Wettstein JG,
    4. Foster RG
    (2010) Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat Rev Neurosci 11:589–599. doi:10.1038/nrn2868 pmid:20631712
    OpenUrlCrossRefPubMed
  34. ↵
    1. Yamaguchi S,
    2. Mitsui S,
    3. Miyake S,
    4. Yan L,
    5. Onishi H,
    6. Yagita K,
    7. Suzuki M,
    8. Shibata S,
    9. Kobayashi M,
    10. Okamura H
    (2000) The 5′ upstream region of mPer1 gene contains two promoters and is responsible for circadian oscillation. Curr Biol 10:873–876. doi:10.1016/S0960-9822(00)00602-3 pmid:10899004
    OpenUrlCrossRefPubMed
  35. ↵
    1. Young ME,
    2. Razeghi P,
    3. Cedars AM,
    4. Guthrie PH,
    5. Taegtmeyer H
    (2001) Intrinsic diurnal variations in cardiac metabolism and contractile function. Circ Res 89:1199–1208. doi:10.1161/hh2401.100741 pmid:11739286
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Zhu Y,
    2. Romero MI,
    3. Ghosh P,
    4. Ye Z,
    5. Charnay P,
    6. Rushing EJ,
    7. Marth JD,
    8. Parada LF
    (2001) Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 15:859–876. doi:10.1101/gad.862101 pmid:11297510
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Zlokovic BV
    (1995) Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res 12:1395–1406. doi:10.1023/A:1016254514167 pmid:8584471
    OpenUrlCrossRefPubMed
  38. ↵
    1. Zlokovic BV
    (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201. doi:10.1016/j.neuron.2008.01.003 pmid:18215617
    OpenUrlCrossRefPubMed
  39. ↵
    1. Zlokovic BV,
    2. Apuzzo ML
    (1997) Cellular and molecular neurosurgery: pathways from concept to reality—part I: target disorders and concept approaches to gene therapy of the central nervous system. Neurosurgery 40:789–803. doi:10.1097/00006123-199704000-00027 pmid:9092853
    OpenUrlCrossRefPubMed
  40. ↵
    1. Zlokovic BV,
    2. Begley DJ,
    3. Chain-Eliash DG
    (1985a) Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res 336:125–132. doi:10.1016/0006-8993(85)90423-8 pmid:3891014
    OpenUrlCrossRefPubMed
  41. ↵
    1. Zloković BV,
    2. Segal MB,
    3. Begley DJ,
    4. Davson H,
    5. Rakić L
    (1985b) Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Res 358:191–199. doi:10.1016/0006-8993(85)90963-1 pmid:3935272
    OpenUrlCrossRefPubMed
  42. ↵
    1. Zloković BV,
    2. Lipovac MN,
    3. Begley DJ,
    4. Davson H,
    5. Rakić L
    (1987) Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain. J Neurochem 49:310–315. doi:10.1111/j.1471-4159.1987.tb03431.x pmid:3585338
    OpenUrlCrossRefPubMed
  43. ↵
    1. Zlokovic BV,
    2. Hyman S,
    3. McComb JG,
    4. Lipovac MN,
    5. Tang G,
    6. Davson H
    (1990) Kinetics of arginine-vasopressin uptake at the blood-brain barrier. Biochim Biophys Acta 1025:191–198. doi:10.1016/0005-2736(90)90097-8 pmid:2364078
    OpenUrlCrossRefPubMed
Back to top

In this issue

The Journal of Neuroscience: 37 (42)
Journal of Neuroscience
Vol. 37, Issue 42
18 Oct 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Advertising (PDF)
  • Ed Board (PDF)
Email

Thank you for sharing this Journal of Neuroscience article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disruption of Bmal1 Impairs Blood–Brain Barrier Integrity via Pericyte Dysfunction
(Your Name) has forwarded a page to you from Journal of Neuroscience
(Your Name) thought you would be interested in this article in Journal of Neuroscience.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Disruption of Bmal1 Impairs Blood–Brain Barrier Integrity via Pericyte Dysfunction
Ryota Nakazato, Kenji Kawabe, Daisuke Yamada, Shinsuke Ikeno, Michihiro Mieda, Shigeki Shimba, Eiichi Hinoi, Yukio Yoneda, Takeshi Takarada
Journal of Neuroscience 18 October 2017, 37 (42) 10052-10062; DOI: 10.1523/JNEUROSCI.3639-16.2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Request Permissions
Share
Disruption of Bmal1 Impairs Blood–Brain Barrier Integrity via Pericyte Dysfunction
Ryota Nakazato, Kenji Kawabe, Daisuke Yamada, Shinsuke Ikeno, Michihiro Mieda, Shigeki Shimba, Eiichi Hinoi, Yukio Yoneda, Takeshi Takarada
Journal of Neuroscience 18 October 2017, 37 (42) 10052-10062; DOI: 10.1523/JNEUROSCI.3639-16.2017
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • blood–brain barrier
  • clock gene
  • pericyte

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Articles

  • Vigilance and behavioral state-dependent modulation of cortical neuronal activity throughout the sleep/wake cycle
  • Brain functional connectivity mapping of behavioral flexibility in rhesus monkeys
  • Accumulation System: Distributed Neural Substrates of Perceptual Decision Making Revealed by fMRI Deconvolution
Show more Research Articles

Neurobiology of Disease

  • Vigilance and behavioral state-dependent modulation of cortical neuronal activity throughout the sleep/wake cycle
  • Brain functional connectivity mapping of behavioral flexibility in rhesus monkeys
  • Accumulation System: Distributed Neural Substrates of Perceptual Decision Making Revealed by fMRI Deconvolution
Show more Neurobiology of Disease
  • Home
  • Alerts
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Issue Archive
  • Collections

Information

  • For Authors
  • For Advertisers
  • For the Media
  • For Subscribers

About

  • About the Journal
  • Editorial Board
  • Privacy Policy
  • Contact
(JNeurosci logo)
(SfN logo)

Copyright © 2022 by the Society for Neuroscience.
JNeurosci Online ISSN: 1529-2401

The ideas and opinions expressed in JNeurosci do not necessarily reflect those of SfN or the JNeurosci Editorial Board. Publication of an advertisement or other product mention in JNeurosci should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in JNeurosci.